23andMe's announcement earlier this month that it had teamed up with Pfizer in inflammatory bowel disease (IBD) could pave the way for the expansion of personalized medicine into a new area.
So far, the personalized approach has mainly been used in cancer to identify patients with certain genetic mutations who are...